Phosphodiesterase Enzyme (PDE) Inhibitors Market becomes an investment hotspot after getting aroused by an elevated occurrence of erectile dysfunction

 

In March 2021, a group of researchers from Karolinska Institute, Stockholm, Sweden concluded the results of their clinical study claiming that the use of PDE5 (Phosphodiesterase type-5) inhibitor in treatment of erectile dysfunction can lower the occurrence of cardiovascular disorders. Additionally, in July 2021, the bio-pharmaceutical company, Arcutis Biotherapeutics, Inc., enrolled the first patient in its Phase III clinical trial on ARQ-154 for treatment of seborrheic dermatitis.

Phosphodiesterase inhibitors are highly effective in combating the adverse effects of Crohn's disease. Enzymes that prevent or regulate the action of Crohn's Disease in the intestines to prevent inflammation and promote the healthy functioning of the intestine. Various proprietary anti-inflammatory (NSAIDs) in the market today are effective in reducing pain and swelling associated with Crohn's and improving the patient's quality of life. Some NSAIDs inhibit the absorption of substances like fatty acids, cholesterol and phospholipids. Oral non-steroidal anti-inflammatory drugs (USIDs) like Aspirin, Ibuprofen and Naproxen are the commonly used NSAIDs for Crohn's disease.

Crohn's and ulcerative colitis are very common inflammatory bowel diseases affecting the large colon. Crohn's affects the lower portion of the small intestine and causes ulcers within the colon. Ulcerative colitis is an inflammatory bowel disease causing inflammation of the colon. Crohn's and ulcerative colitis are affected by a variety of gastrointestinal (GI) medications including sulfasalazine, balsalazide and vincristine.

Besides these two serious inflammatory bowel diseases, there are a number of other conditions that respond well to the use of inhibitors. Non-alcoholic steatohepatitis (NASH) is a condition where the protective mucus layer in the stomach is replaced with a villous lining from the outside of the body.

Rising drug abuse cases are leading to a surge in erectile dysfunction (ED) conditions in men amidst changing lifestyles, which, in turn, are creating positive growth prospects for the phosphodiesterase enzyme (PDE) inhibitors market. Plus, the amalgamation of factors such as hyperlipidemia, prostate cancer, high blood pressure, diabetes, testosterone insufficiency, and overweight is broadening the scope for the phosphodiesterase enzyme (PDE) inhibitors market. On the contrary, the complications associated with PDE inhibitors along with the advent of generic drugs can cause a serious dent in the progress of the phosphodiesterase enzyme (PDE) inhibitors market.

Throughout the globe, the phosphodiesterase enzyme (PDE) inhibitors market in the North American region is likely to propel at a scalable rate on the heels of rising incidences of chronic disease coupled with the increased healthcare expenditure. In parallel, the Asia Pacific is also proving to be fruitful for the phosphodiesterase enzyme (PDE) inhibitors market owing to the growing number of erectile dysfunction cases compounded with the hormonal deficiencies among the population.